SDGR icon

Schrodinger

25.63 USD
-0.15
0.58%
At close Apr 30, 4:00 PM EDT
After hours
25.63
+0.00
0.00%
1 day
-0.58%
5 days
0.39%
1 month
29.84%
3 months
0.79%
6 months
45.79%
Year to date
25.64%
1 year
5.13%
5 years
-44.76%
10 years
-10.51%
 

About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Employees: 787

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

48% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $6.93M

26% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 27

7% more capital invested

Capital invested by funds: $1.12B [Q3] → $1.19B (+$77.5M) [Q4]

2.69% more ownership

Funds ownership: 94.5% [Q3] → 97.19% (+2.69%) [Q4]

2% more funds holding

Funds holding: 205 [Q3] → 210 (+5) [Q4]

15% less repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 75

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$32
25%
upside
Avg. target
$39
50%
upside
High target
$45
76%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Keybanc
Scott Schoenhaus
54% 1-year accuracy
21 / 39 met price target
25%upside
$32
Overweight
Maintained
16 Apr 2025
Piper Sandler
Joseph Catanzaro
50% 1-year accuracy
12 / 24 met price target
76%upside
$45
Overweight
Maintained
27 Feb 2025

Financial journalist opinion

Based on 7 articles about SDGR published over the past 30 days

Neutral
Business Wire
2 days ago
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related.
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
Neutral
Business Wire
1 week ago
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
Negative
MarketBeat
1 week ago
3 Momentum Stocks That Could Soar Post-Market Volatility
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
3 Momentum Stocks That Could Soar Post-Market Volatility
Neutral
Business Wire
1 week ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
2 weeks ago
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur.
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
Positive
Zacks Investment Research
2 weeks ago
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Positive
Seeking Alpha
2 weeks ago
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)
Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety.
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)
Neutral
Business Wire
1 month ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025.
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen
Neutral
Seeking Alpha
1 month ago
Schrödinger: Still Waiting On A Catalyst
Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing.
Schrödinger: Still Waiting On A Catalyst
Charts implemented using Lightweight Charts™